United States Antithrombotic Drugs Market Insight
Published: 04 June 2026 | Report Format: Electronic (PDF)
The United States Antithrombotic Drugs Market is projected to grow at a CAGR of around 7.1%, driven by the rising prevalence of cardiovascular diseases, increasing incidence of thrombotic disorders, growing adoption of novel anticoagulants, and ongoing advancements in antithrombotic therapies.
United States Antithrombotic Drugs Market Forecasts to 2035
- The United States Antithrombotic Drugs Market Size Was Estimated at USD 18.7 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 7.1% from 2025 to 2035.
- The United States Antithrombotic Drugs Market Size is Expected to Reach around USD 37.1 Billion by 2035.
Notable Insights the United States Antithrombotic Drugs Market
- Segmentation Based on Drug Class, the Anticoagulants segment held a dominant position in the United States Antithrombotic Drugs Market in 2025 with nearly 64% share, driven by their widespread use in preventing stroke, deep vein thrombosis, pulmonary embolism, and other thromboembolic disorders.
- Segmentation Based on Application, the cardiovascular diseases segment accounted for approximately 52% share in 2025, supported by the high prevalence of atrial fibrillation, coronary artery disease, increasing aging population, and growing adoption of preventive antithrombotic therapies. thrombotic risk, and growing adoption of preventive antithrombotic therapies.
- The United States Antithrombotic Drugs Market is driven by Bristol Myers Squibb, Pfizer Inc., and Johnson & Johnson, with combined revenues of approximately USD 202.3 billion in 2025. The market is expected to grow at a CAGR of 7.1%.
- Rising cardiovascular disease prevalence, increasing incidence of thrombotic disorders, and growing adoption of novel oral anticoagulants are expected to drive market growth, with antithrombotic drug utilization increasing by nearly 34% and advanced therapy adoption expanding by approximately 29% by 2035.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
- Intelligent Market Research Based on AI for Semiconductors & Optoelectronics
Decisions Advisors offers intelligent market research which includes advanced analysis of infrared sensor technologies, optoelectronic semiconductors, AI-driven sensing solutions, and remote sensing. Our research identifies potential areas of business development, technology adoption rates, competitive position analysis, and important strategic changes in South Korea Remote Sensing Infrared Light Emitting Diode Market.
- Highly Effective Research Approaches with Accurate Forecast Analysis
The research process uses advanced methodologies such as primary research interview approaches, industry research, tracking the semiconductor value chain, and data triangulation to deliver accurate market sizing, CAGR forecasting, investment analysis, and technology forecasting. The study examines the demand for semiconductor solutions in automotive electronics, industrial automation, health care monitoring, and smart surveillance applications in South Korea.
- Highly Competitive Environment Analysis
In-depth analysis of key infrared LED players, optoelectronic semiconductor innovations, AI-enabled sensing solutions, product launch activities, and collaborations is included in the report. The report also covers semiconductor regulations, technology research and development analysis, smart sensor infrastructure, and new opportunities available in the South Korea Remote Sensing Infrared Light Emitting Diode Market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States antithrombotic drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies United States Antithrombotic Drugs Market
- Bristol Myers Squibb
- Pfizer Inc.
- Johnson & Johnson
- Bayer AG
- Sanofi
- Boehringer Ingelheim
- Daiichi Sankyo Company, Limited
- Novartis AG
- Abbott Laboratories
- Merck & Co., Inc.
Recent Developments:
- In September 2025, Bristol Myers Squibb expanded the U.S. indication for its anticoagulant portfolio, strengthening stroke prevention and thromboembolic disorder management while supporting broader adoption of advanced antithrombotic therapies.
- In June 2025, Johnson & Johnson collaborated with Bristol Myers Squibb on real-world evidence initiatives in the United States, focusing on anticoagulant treatment outcomes, cardiovascular risk reduction, and optimized patient care strategies.
Market Segmentation:
United States Antithrombotic Drugs Market, By Drug Class
• Anticoagulants
• Antiplatelet Drugs
• Thrombolytic Agents
• Direct Oral Anticoagulants (DOACs)
• Heparins & Low Molecular Weight Heparins (LMWHs)
• Vitamin K Antagonists
• Other Antithrombotic Drugs
United States Antithrombotic Drugs Market, By Route of Administration
• Oral
• Injectable
• Intravenous
United States Antithrombotic Drugs Market, By Application
• Atrial Fibrillation
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Acute Coronary Syndrome (ACS)
• Stroke Prevention
• Other Thrombotic Disorders
United States Antithrombotic Drugs Market, By End User
• Hospitals
• Specialty Cardiology Clinics
• Ambulatory Surgical Centers (ASCs)
• Home Healthcare Settings
• Research & Academic Institutes
United States Antithrombotic Drugs Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Wholesalers & Distributors
• Government Procurement Programs
• Direct Sales Channels
Expert Views:
The United States Antithrombotic Drugs Market is positioned for sustained growth through 2035, supported by the increasing burden of cardiovascular and thromboembolic disorders, expanding utilization of novel anticoagulants, and continuous therapeutic advancements. Strong demand across healthcare settings, favorable clinical outcomes, and ongoing innovation by leading pharmaceutical companies are expected to strengthen market expansion, enhance treatment accessibility, and drive long-term industry development.
Author: Govind and Krishna By Spherical Insights and Consulting